Targets › CD45RA
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2031.
Open in Phaseline: the race on CD45RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Hospital of Philadelphia | CD45RA Depleted Stem Cell Addback (CD45RO+ T cells) CD45RA-depleted, CD45RO+ memory T cell addback to accelerate immune reconstitution post TC | CD45RA | Phase 1 | Leukemia | Mar 2031 |
Leukemia (1)
–
Children's Hospital of Philadelphia (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.